A historical recount of chordoma

Ronald Sahyouni, MS,1 Khodayar Goshtasbi, BS,1 Amin Mahmoodi, BS,2 and Jefferson W. Chen, MD, PhD1,2

1School of Medicine and 2Division of Neurotrauma, Department of Neurological Surgery, University of California, Irvine, California

Chordoma, a rare bone tumor that occurs along the spine, has led scientists on a fascinating journey of discoveries. In this historical vignette, the authors track these discoveries in diagnosis and treatment, noting events and clinicians that played pivotal roles in our current understanding of chordoma. The study of chordoma begins in 1846 when Rudolf Virchow first observed its occurrence on a dorsum sellae; he coined the term “chordomata” 11 years later. The chordoma’s origin was greatly disputed by members of the scientific community. Eventually, Müller’s notochord hypothesis was accepted 36 years after its proposal. Chordomas were considered benign and slow growing until the early 1900s, when reported autopsy cases drew attention to their possible malignant nature. Between 1864 and 1919, the first-ever symptomatic descriptions of various forms of chordoma were reported, with the subsequent characterization of chordoma histology and the establishment of classification criteria shortly thereafter. The authors discuss the critical historical steps in diagnosis and treatment, as well as pioneering operations and treatment modalities, noting the physicians and cases responsible for advancing our understanding of chordoma.

https://thejns.org/doi/abs/10.3171/2017.7.SPINE17668

KEY WORDS chordoma; historical vignette; neurosurgery; spine; tumor; oncology

History of Pathology and Clinical Descriptions

The story of chordoma begins in 1846 when the prolific German physician and pathologist Rudolf Virchow (Fig. 1) noted on autopsy an incidental, small, slimy growth on the surface of the clivus blumenbachii (dorsum sellae).4 In 1856, during a routine postmortem autopsy, the German anatomist Hubert von Luschka coincidentally stumbled upon a similar soft, transparent, lobulated mass that entered the cranial cavity at the sella turcica.6,27,31 Perplexed by this finding, Virchow conducted a histological investigation, and within a year of von Luschka’s observations, Virchow became the first to fully describe and name this peculiar tumor. In 1857, Virchow coined the term “chordomata,” and in his description, he noted its interesting embryonic character and referred to it as an “ecchondrosis physalifora spheno-occipitalis,” which directly translates to a “cartilaginous physaliphorous” lesion of the cartilaginous junction between the basisphenoid and basioccipital bones.27,31 He essentially believed that chordomata was a cartilaginous neoplasm caused by softening of the cartilage matrix and degradation of surrounding tissues, which leads to excess water accumulation and vesicular transformation of the cells.5,27,31 He used the word “physaliphora” (physaliphorous) in reference to the many cytoplasmic vacuoles seen on microscopic examination. This is a pathognomonic feature of chordoma to this day (Fig. 2).20

In 1858, Virchow’s doctoral advisor, German anato-
mist Johannes Peter Müller, postulated that chordomata may originate from notochordal tissue. Müller’s hypothesis was based on the fact that most vertebrates, including humans, contain remnants of notochordal tissue in the basilar cartilage, sacrum, and spheno-occipital synchondrosis (analogous to the nucleus pulposus of intervertebral discs). Unfortunately, Müller did not have sufficient evidence at the time to verify his beliefs; thus, Virchow, Luschka, and other peers rejected his theory. Müller’s hypothesis became the subject of dispute and inspired concentrated interest on describing the pathological development and characteristics of chordomata, specifically with regard to the development of the notochord, especially among Virchow, von Luschka, Kölliker, Löwe, Fric, and Heiberg. Virchow’s view, that chordomata derives from cartilage and not notochord, became almost universally accepted in 1880 after the Belgian physician and anatomist Hector Leboucq noted that notochordal tissue is destroyed before birth in human embryos and that intervertebral notochordal expansion is replaced by connective tissue. Virchow’s view, that chordomata derives from cartilage and not notochord, became almost universally accepted in 1880 after the Belgian physician and anatomist Hector Leboucq noted that notochordal tissue is destroyed before birth in human embryos and that intervertebral notochordal expansion is replaced by connective tissue. Although incorrect and contradictory to many published works of the time, this conclusion was widely accepted and influenced others to believe in Virchow’s initial postulation; some, however, remained skeptical and continued further research into the matter.

After 36 years of debate over Müller’s notochordal hypothesis, observations by the German pathologist Moritz Wilhelm Hugo Ribbert lent more credibility to the view that chordoma is derived from notochord. In 1894, after reviewing 5 cases of clival chordomata, Ribbert proposed a set of arguments supporting acceptance of Müller’s view. He first argued that all observed cases of chordomata had originated from the midline of the clivus. He then asserted that no case of chordomata had presented as a transition from cartilage to cancerous tissue; thus, these tumors merely coexisted as intracartilaginous notochordal vestiges. Furthermore, he pointed out that in a cartilaginous tumor, one does not observe a gelatinous texture coincident with a physaliphorous appearance. Later that same year, Ribbert conducted an experiment to further prove the notochordal hypothesis and his added reasons. In his 1894 experiment, Ribbert punctured the intervertebral discs of a group of rabbits, which caused herniation of the nucleus pulposus and the proliferation of tissue histologically similar to that of chordomata. On autopsy examination, he found notochordal tissue in the clivus of approximately 2% of the rabbit corpses.

In the meantime, the intense focus on a pathological description caused no real clinical description to be noted. The first-ever symptomatic description of a patient with sphenop-occipital chordomata was given in 1864 by Arnold C. Klebs, a Swiss physician. In 1904, Ribbert conducted a series of 500 autopsies, in which he identified 10 cases of clival chordomata, an incidence of 2%, which is similar to the incidence he had observed in his rabbit experiment. Later that year, he proposed the name “chordoma,” instead of chordomata, to designate this tumor.

Up to this point, chordomas were mainly thought of as benign, slow-growing tumors. Most physicians did not consider this tumor to cause death, until in 1903, when
Grahl recorded the first case resulting in death, in which a tumor had caused an increase in intracranial pressure and involved the brainstem. Grahl’s patient, a 51-year-old woman, presented with neurological symptoms, including headaches, deafness, and visual impairment caused by paralysis of the third, fourth, and seventh cranial nerves. Furthermore, she presented with dysarthria and dysphagia and eventually died from paralysis of the medullary centers. On autopsy, Grahl found a 3-cm tumor in the sella turcica, resembling a chordoma. Soon thereafter, in 1907, physicians Fischer and Steiner brought attention to the likely clinically malignant nature of chordoma after a 16-year-old boy presented with numerous progressing neurological symptoms, which eventually led to his death. The boy’s autopsy exposed a chordoma causing extensive degeneration of the brain via destruction of posterior structures down to the second cervical vertebra.

In 1909, the physician Linck presented a case of considerable pathological interest. A middle-aged man had presented with a mass the “size of a pigeon’s egg” in his pharynx, resulting in auditory discharge and otitis. Within a month, 2 operations were performed, and greasy mucoid material, which proved to be chordoma tissue, was obtained. This was the first demonstration of nasopharyngeal chordoma, which prompted Linck to establish a set of histological characteristics to describe and identify chordoma regardless of where it occurs. He noted the formation of intra- and extracellular mucus, lobular and chordal arrangement of physaliferous mucus-containing cells, and similarity of the tumor to notochordal tissue of the nucleus pulposus as key characteristics of chordoma.

In 1910, physicians Feldmann and Mazzia reported the first official case of a sacrococcygeal chordoma in a 46-year-old woman. This patient had a yearlong progressive soft swelling of the sacro-perineal region, which proved to be chordoma tissue. Soon after, in 1919, Pototschnig recorded the first observed case of metastatic chordoma. His patient presented with a sacrococcygeal chordoma that had recurred after operation and had produced a metastasis to the regional lymph nodes.

After publishing a series of papers from 1914 to 1922, physician-scientists Alezais and Peyron presented 3 histological criteria for the development of chordoma, which directly correlate to the classic stages of the evolution of the primitive notochord. First, a hollow tube lined with endodermal tissue arises. Then, this tube is transformed to a solid cord of tightly packed undifferentiated cells (instead of polyhedral epithelial cells typically found in chorda dorsalis). Last, the cells become vacuolated, fibribillate, and produce mucin, which aids in adaptation of a supportive structure.

A year later, in 1923, after reviewing various chordoma cases, Stewart and Burrow suggested using the term “ecchondrosis physaliphora” (instead of Virchow’s initial “ecchondrosis”) to classify nonaggressive nests of the notochord without malignant growth potential and “chordoma” (Fig. 3) for the invasive forms of the disease. This distinction was crucial, for the word “ecchondrosis” acknowledged the chordoma’s notochordal origin, as opposed to a cartilaginous origin, and separated the harmless benign form from the true neoplasm (chordoma). Stewart and Burrow suggested that the more solid and opaque the tumor was, the less mucous it would produce and the more malignant it would become.

In the late 1920s and early 1930s, the first high-quality literature reviews were conducted by Coenen (1925), Corsy and Surmont (1927), and Stewart and Morin (1926). These reviews had great impact on the overall understanding of the disease. In the 1925 review, Coenen, a German surgeon, studied 68 cases of various chordomas and, based on given clinical and embryological descriptions, proposed the first classification for the different forms of chordoma, a table that was used and modified in every paper thereafter. In 1935, Mabrey, an American physician from Boston, Massachusetts, reviewed the first 150 cases of chordoma ever reported and created an elaborate observational report to evaluate this disease and its standard of care. Mabrey’s retrospective study used Coenen’s classifications and revealed a much higher prevalence of sacrococcygeal and cranial tumors than lesions of the mobile spine. In addition, he noted an average survival of 17.5 months after symptom onset, a higher incidence of disease in men, increased survival after resection in sacrococcygeal cases, and a lack of characteristic symptoms for any form of the disease.

Furthermore, Mabrey observed symptoms unique to various types of chordoma. He reported that cranial chordoma is often accompanied by a dull and rarely neurological headache, as opposed to vertebral chordoma, which commonly presents with sharp pain with radiculopathy, and sacrococcygeal chordoma, which often presents with dull yet prominent pain. Cranial chordoma can also lead to visual disturbance and dizziness. Weakness and paralysis in the lower extremities are commonly seen in vertebral chordomas.

In 1952, pathologist Charles Congdon replicated Ribbert’s original rabbit experiment. By demonstrating nucleus pulposus cell regeneration following intervertebral disc puncture, Congdon confirmed Müller’s hypothesis of chordoma’s notochordal origin. In 1973, Heffelfinger and
colleagues, from the Mayo Clinic in Minnesota, defined the more clinically benign and cartilaginous-like chordoid chordoma variant with neoplastic cells. Six years later, the 4 types of clival tumor extensions were discussed for the first time by Nolte, a pediatric radiologist from Tübingen, Germany. Of the anterior, posterior, superior, and inferior extensions he defined, Nolte noted that children younger than 5 mainly presented with clival tumors with inferior extensions.

**History of Diagnosis**

For the first 80 years of chordoma’s history, the only clear way to recognize it was through autopsy or biopsy. Not until 1922 did the physician Micotti use exploratory puncture to correctly diagnose a patient with sacrococcygeal chordoma, and in 1926, another physician, named Adler, used radiographic imaging to correctly diagnose 5 patients with sacrococcygeal chordoma. The extreme difficulty in diagnosing such tumors was noted by Mabrey, who, in 1935, discussed possible diagnostic tools for various types of chordomas. In cranial chordoma, diagnosis could potentially be determined via clivus or clinoidal defects seen on radiographic imaging, increased intracranial pressure measurements, or exploratory punctures. In vertebral chordoma, vertebral destruction could be seen on radiographs because of the chordoma’s nucleus pulposus origin. In addition, long-term pressure from tumor mass effect could lead to xanthochromia and vertebral fracture in patients. Lastly, sacrococcygeal chordoma could present on radiography with a soft-tissue shadow accompanied by bone destruction. Inspection for enlarged vacuolated cells with homogeneous mucoid substances was the most appropriate initial diagnostic step if sacrococcygeal chordoma was suspected. Unfortunately, only 12% of these cases were correctly diagnosed at the time of Mabrey’s report.

In 1955, Shackelford and Rhode, who focused on sacrococcygeal chordoma, observed that many cases presented with presacral masses that were potentially detectable through digital palpation of the posterior rectum and that the mass mostly did not adhere to the overlying skin. Moreover, they saw that roentgenological data could reveal radiotranslucency, which suggests sacral destruction or rarefaction. They concluded that clinicians could confirm diagnoses solely by aspiration biopsy or by intraoperative procurement of the specimen and subsequent frozen section.

The existence of chordoid chordoma, defined by Helfinger and mentioned above, was questioned until 1994, when an organographic examination by Ishida and Dorfman, pathologists in the orthopedic surgery department at Albert Einstein College of Medicine, established a classification scheme for this chordoma variant: 1) predominately chordoid pattern and small chordoid foci, 2) equal volumes of chordoid and chordoid components, and 3) cytokeratin and epithelial membrane antigen positivity. Negative-stained cartilaginous tumors containing chordoid elements became recognized as chordosarcomas.

Another important aspect of chordoma diagnosis deals with chordoma genetics. Our recent understanding of the genetics of chordoma stems from notable familial chordoma patients, starting with Foote and colleagues’ discussion of a case involving middle-aged siblings experiencing familial sacrococcygeal chordomas, which paved the way for other discussions on familial cases. Despite reports of congenital chordomas, the youngest reported patient with a positive family history was 3 years old. Cytogenetic examinations of 2 daughters and their father suspected of familial chordoma showed karyotypic heterogenic hypo- or diploidy. Furthermore, fluorescence in situ hybridization showed dic(1;9)(p36.1;p21) clonal and nonclonal chromosomal rearrangements, with notable unbalanced translocation in chromosome 1p. Since the genetics of chordoma is technical and beyond the scope of this historical paper, we recommend further reading regarding the genetics and biological basis of chordoma.

**History of Surgical Treatment**

In 1919, Daland, a physician at the Massachusetts General Hospital, operated on the first spheno-occipital case. A woman, age 30, who had endured symptoms for 3 years, presented with a tumor extending from the region of the right ear into the neck. There was a bulging into the right auditory canal, as well as decreased sensation and atrophy of the right side of the tongue. The tumor in the neck was curedtted, and its connection with the base of the skull was established. Recurrence took place despite radiation therapy; however, the patient was alive at the time the case was published.

In a 1923 case report, Hirsch described an operation on a nasopharyngeal chordoma via splitting the palate; the tumor recurred 1 year later. In 1928, Aruga and Clermont reported on the transsinusos-facial removal of a 48-year-old woman’s nasopharynx chordoma; the tumor returned months later. During the same year, Loebell described a surgical antrum approach and radium treatment of a left nasopharynx chordoma in a 62-year-old man experiencing vertigo and symptoms in the left ear and left nostril, who also demonstrated radiographic defects in the petrous bone and sella turcica. The tumor returned 1.5 years later, followed by death.

In a 1955 review focused on sacrococcygeal chordoma, Shackelford and Rhode reported that the earliest tumor excisions, often performed with piecemeal removal via local curettage, resulted in boney remnants leading to tumor recurrence. Surgical treatments later advanced to anteriorly or posteriorly approached en bloc excisions of sacrum, coccyx, and chordoma, while sparing the rectum. The sacral bone was transected at subjectively safe levels above the chordoma’s extracranial base.

In a 1960 publication by Hungarian neurosurgeons Zoltan and Fenyes, records of various initial operations to treat cranial chordomas were noted. According to these authors, the first transnasal operation occurred in 1911, the first craniotomy in 1918, and the first suboccipital craniotomy and decompression in 1923. They also noted that the first resection through the upper jaw or palate occurred in 1923, the first transfrontal exposure through ethmoidal cells in 1929, and the first cerebellar craniotomy, transfrontal craniotomy, and transsphenoidal resection in 1941.
1941, and 1953, respectively.\textsuperscript{59} In 1966, neurosurgeons at the University of California, San Francisco, described a transcervical transclival approach for resection of a clivus chordoma; they postulated that a transcervical approach would help to prevent hemorrhage and meningeal infection.\textsuperscript{39}

**History of Radiotherapy**

In 1919, Porter and Daland tested out “two massive x-ray treatments” on their patient; however, the efficacy of radiation was not yet known.\textsuperscript{14} In 1955, Shackelford reported radiotherapy to be ineffective on its own, with only potential pain relief in inoperable patients. He reported a maximum 5-year survival rate following radiotherapy alone and noted that its addition to surgery was never seen to prevent tumor recurrence.\textsuperscript{46}

In 1964, researchers demonstrated that radiation dosages above 5000 rad prolonged remission. Three years later, Higinbotham, an American pathologist at Memorial Sloan Kettering, showed that a minimum 7000-rad dosage was needed for beneficial results.\textsuperscript{25,38} In 1970, Pearlman and Friedman, from New York University Hospital’s Department of Radiation Therapy, assessed the photon radiotherapy dosage in tumor control and reported an 80% success rate with 80 Gy of radiation as opposed to a 20% success rate in the 40- to 60-Gy radiation groups.\textsuperscript{2,43} In 1986, Dr. Amendola reported that radiotherapy was most effective if administered postresection.\textsuperscript{2,41}

Proton beam therapy is an alternative to conventional radiotherapy, especially when tumors are located in sensitive or critical locations, namely skull base chordomas.\textsuperscript{34} This charged-particle therapy provides an excellent and conformal dose distribution with no exit dose.\textsuperscript{34} In 1982, Suit et al., from the Massachusetts General Hospital, used proton beam radiotherapy in 10 chordoma and sarcoma patients and described local control with no complications in any of the patients.\textsuperscript{5} Proton beam therapy remains an active field of research but is beyond the scope of this review; however, excellent papers covering proton beam therapy are readily available.\textsuperscript{3} We recommend focused articles and reviews for further information regarding current state-of-the-art radiation therapy and proton beam therapy in treating chordoma.\textsuperscript{16,44}

**Evolution to Current Treatment**

There have been many developments in the fields of chordoma molecular biology, genetics, and multimodal treatment approaches since the initial characterization of this tumor in 1846. Even in the present day, chordoma remains poorly responsive to conventional chemotherapy and radiotherapy, leaving radical resection as the most common option despite a 26.7%–66.7% recurrence rate and 65% 5-year survival.\textsuperscript{30,56,60} Given this high rate of recurrence, chordoma treatment has recently focused on prognostic stratification of patients based on neoplasm location (40% of chordomas occur at the clivus or cervical spine, and 60% occur at the sacrococcygeal junction of the spine), protein and genetic biomarker expression (for example, brachyury or bone morphogenetic protein 4 [BMP4] expression, or loss of genetic material), epigenetic modifications, and a variety of clinical and demographic criteria (for example, age and sex).\textsuperscript{18,30,37,41,60} Brachyury, for example, is a transcription factor of the T-box family that is a sensitive and specific marker that is readily expressed in chordoma and thought to serve as an important diagnostic and prognostic biomarker.\textsuperscript{59} Other markers, such as sex steroid receptors COX-2 and ER-β, have implicated age and sex in the prognostic outcomes of chordoma patients.\textsuperscript{13} This recent work has led to a variety of clinical trials with targets ranging from molecular targets and brachyury to EZH2 (a transcriptional regulator).\textsuperscript{19}

Multimodal treatment approaches have significantly altered the therapeutic paradigms for chordoma patients over recent decades. In patients with inoperable and progressive disease, imatinib has been shown to arrest tumor growth.\textsuperscript{26} Chemotherapy (for example, imatinib) and radiotherapy (for example, pencil beam scanning proton therapy) combined with resection, as compared with unimodal therapy, have significantly enhanced the 7-year metastasis-free and overall survival rates in patients.\textsuperscript{54} With respect to clival chordomas, multimodal approaches include craniotomy or endoscopic approaches, in an either staged or simultaneous fashion, combined with adjuvant intensity-modulated radiation therapy (IMRT), proton beam therapy, or Gamma Knife surgery.

Even with the current understanding of surgical, radiosurgical, and medical management of chordoma, a significant bulk of the underlying chordoma pathobiology remains unknown, as evidenced by the high rate of recurrence.\textsuperscript{9,53} Active research on tyrosine kinase and STAT3 transcription manipulation, as well as tyrosine kinase inhibitor therapies such as nilotinib and dasatinib, has shown potential.\textsuperscript{42,47,53,58} It has also been reported that Notch and MAPK receptor pathways with their corresponding microRNAs (miRNAs) may play critical roles in chordoma biology.\textsuperscript{15} Furthermore, characterizing the chordoma cell line may facilitate investigations into targeted therapy aimed at arresting tumor growth.\textsuperscript{28,53,57} Carbon ion radiation therapy has been shown to be effective in treating skull base chordoma.\textsuperscript{52} Gamma Knife surgery to treat skull base chordoma is an active field of interest, and we recommend additional reading regarding its qualifications and outcomes.\textsuperscript{15,23} A review by Kayani et al. concluded that wide-margin resection offers the best prognosis for sacral chordoma; however, further investigation into the exact benefits of radiotherapy for patients with inadequate operative margins is warranted.\textsuperscript{52} The significant heterogeneity and rarity of chordoma makes it difficult to conduct randomized trials to assess differences among surgery, radiosurgery, and combinatorial therapy.\textsuperscript{48} Lastly, we recommend implementing new therapeutic evaluation metrics for chordoma, with a focus on quality of life outcomes, growth modulation index, change in contrast and PET response, and the tumor’s degree of circulating DNA.\textsuperscript{48}

In Figure 4, we provide a historical timeline summarizing the foundational discoveries and pioneering therapeutic events concerning chordoma.

**Conclusions**

The recognition and treatment of chordoma as a histo-
logically benign tumor with malignant pathophysiologica
manifestation has greatly evolved over the past 170 years. Th
initial discovery came from Virchow with contributio
from Luschka and Müller, with the latter correctly hypothesizing th
chordoma had a notochord origin. Thereafter, a multitude of autopsy and case studies led to initia
classifications and diagnostic guidelines that estab
chordoma’s malignancy, contrary to prior beliefs. Both surgical and radiation therapies to treat chordoma were ini
tiated by Daland’s tumor curette operation, follo
by x-ray radiation. A series of initially reported cas
es of various forms of chordoma, such as sphen-o-occipital,
vertebral, sacrococcygeal, nasopharyngeal, and metastatic
chordoma, led to a better understanding of diagnosis and treatment.

Acknowledgments
Mr. Sahyouni is funded in part by a Medical Scientist Training Program grant from the NIH (T32-GM08620).

References
3. Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Mr. Sahyouni is funded in part by a Medical Scientist Training Program grant from the NIH (T32-GM08620).

FIG. 4. Historical timeline of the fundamental discoveries and pioneering therapeutic milestones. Figure is available in color online only.

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Chen, Sahyouni. Acquisition of data: Sahyouni, Goshtasbi, Mahmoodi. Analysis and interpretation of data: all authors. Drafting the article: all authors. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Chen. Study supervision: Chen, Sahyouni.

Correspondence
Jefferson W. Chen: UC Irvine Medical Center, Orange, CA. jeffewecl@uci.edu.